KR20070011458A - 키나제의 벤조트리아진 억제제 - Google Patents

키나제의 벤조트리아진 억제제 Download PDF

Info

Publication number
KR20070011458A
KR20070011458A KR1020067023392A KR20067023392A KR20070011458A KR 20070011458 A KR20070011458 A KR 20070011458A KR 1020067023392 A KR1020067023392 A KR 1020067023392A KR 20067023392 A KR20067023392 A KR 20067023392A KR 20070011458 A KR20070011458 A KR 20070011458A
Authority
KR
South Korea
Prior art keywords
disease
compound
individual
mmol
treating
Prior art date
Application number
KR1020067023392A
Other languages
English (en)
Korean (ko)
Inventor
글렌 노론하
캐티 바레트
지앙구오 카오
콜렌 그리첸
시안창 공
존 후드
치 칭 막
앤드류 맥퍼슨
베드 프라카시 퍼택
조엘 레닉
리차드 솔
우테 스플리트게르버
볼프강 라시들로
빈키 젱
닝닝 자오
엘레나 드네프로브스카이아
Original Assignee
탈자진 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 탈자진 인코포레이티드 filed Critical 탈자진 인코포레이티드
Publication of KR20070011458A publication Critical patent/KR20070011458A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
KR1020067023392A 2004-04-08 2005-04-07 키나제의 벤조트리아진 억제제 KR20070011458A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56123704P 2004-04-08 2004-04-08
US60/561,237 2004-04-08
US64343905P 2005-01-12 2005-01-12
US60/643,439 2005-01-12

Publications (1)

Publication Number Publication Date
KR20070011458A true KR20070011458A (ko) 2007-01-24

Family

ID=35125563

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067023392A KR20070011458A (ko) 2004-04-08 2005-04-07 키나제의 벤조트리아진 억제제

Country Status (10)

Country Link
US (3) US7456176B2 (US07456176-20081125-C00483.png)
EP (2) EP2543376A1 (US07456176-20081125-C00483.png)
KR (1) KR20070011458A (US07456176-20081125-C00483.png)
AU (1) AU2005231507B2 (US07456176-20081125-C00483.png)
CA (1) CA2567574C (US07456176-20081125-C00483.png)
HK (1) HK1110578A1 (US07456176-20081125-C00483.png)
IL (1) IL178908A (US07456176-20081125-C00483.png)
NZ (2) NZ551027A (US07456176-20081125-C00483.png)
RU (1) RU2006139258A (US07456176-20081125-C00483.png)
WO (1) WO2005096784A2 (US07456176-20081125-C00483.png)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
EP1549614A4 (en) * 2002-10-03 2008-04-16 Targegen Inc VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
EP2543376A1 (en) * 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
JP5275628B2 (ja) * 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
GB0501999D0 (en) * 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CN103012254A (zh) 2005-05-10 2013-04-03 英特芒尼公司 用于调节应激-活化蛋白激酶系统的吡啶酮衍生物
MX2007008848A (es) * 2005-06-08 2008-04-16 Targegen Inc Metodos y composiciones para el tratamiento de desordenes oculares.
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CA2628283C (en) * 2005-11-01 2017-06-27 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
RU2008127486A (ru) * 2005-12-08 2010-01-20 Милленниум Фармасьютикалз, Инк. (Us) Бициклические соединения с ингибиторной активностью в отношении киназы
US7691858B2 (en) * 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
CN101583365B (zh) 2006-12-15 2012-09-26 阿布拉西斯生物科学公司 三嗪衍生物及其治疗应用
WO2010008411A1 (en) * 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
US8691573B2 (en) 2008-12-03 2014-04-08 The Scripps Research Institute Stem cell cultures
JP2012514020A (ja) 2008-12-29 2012-06-21 フォーヴィア・ファーマシューティカルズ 置換キナゾリン化合物
CN102317288A (zh) 2009-02-13 2012-01-11 佛维雅制药公司 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶
GB0908905D0 (en) 2009-05-26 2009-07-01 Sentinel Oncology Ltd Pharmaceutical compounds
EP2440057A4 (en) 2009-06-09 2012-12-05 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
AR081960A1 (es) * 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
EP2447256A1 (en) * 2010-10-21 2012-05-02 Laboratorios Lesvi, S.L. Process for obtaining dronedarone
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
WO2016089208A2 (en) 2014-12-04 2016-06-09 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents
JP7023080B2 (ja) 2016-10-31 2022-02-21 東ソー株式会社 芳香族化合物の製造方法
CN116410159B (zh) * 2023-06-09 2023-08-22 济南国鼎医药科技有限公司 一种恩曲替尼中间体的制备方法及其应用

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003199A (en) 1930-05-31 1935-05-28 Johnson Frank James Automatic coal stoker
US2003149A (en) 1931-05-22 1935-05-28 Autographic Register Co Manifolding
US2003065A (en) 1931-06-20 1935-05-28 John R Ditmars Composition for coating sheets, fibrous stocks, and the like
US2004102A (en) 1932-02-24 1935-06-11 Daniel A Dickey Hollow steel propeller construction
US2004138A (en) 1932-11-30 1935-06-11 Byers A M Co Method of making wrought iron pipe
US2002165A (en) 1933-07-08 1935-05-21 Charles A Winslow Air cleaner
US2003187A (en) 1933-10-02 1935-05-28 Frederick H Shaw Automobile radio device
US2003166A (en) 1933-10-26 1935-05-28 Zancan Ottavio Front drive for motor cars
US2001051A (en) 1933-12-01 1935-05-14 Angelina Mariani Tamperproof meter box with cutout control and fuse drawer for electric meters
US2004092A (en) 1933-12-15 1935-06-11 John L Chaney Device for indicating the temperature of liquids
US2003060A (en) 1934-04-02 1935-05-28 Ernest L Heckert Thermostatic controlling device
US2667486A (en) 1951-05-24 1954-01-26 Research Corp 2,4-diamino pteridine and derivatives
IL26578A (en) 1965-10-04 1970-11-30 Merck & Co Inc Pethridine compounds and their preparation
DE2255947A1 (de) 1972-11-15 1974-05-22 Bayer Ag Substituierte 3-amino-benzo-1,2,4triazin-di-n-oxide (1,4), verfahren zu ihrer herstellung sowie ihre verwendung als antimikrobielle mittel
IL44058A (en) 1973-02-02 1978-10-31 Ciba Geigy Ag 3amino-1,2,4-benzotriazine 1,4-di-noxide derivatives, their preparation and compositions for the control of microorganisms containing them
FR2275461A1 (fr) 1974-06-18 1976-01-16 Labaz Nouveaux stabilisants des polymeres et copolymeres du chlorure de vinyle
AU535258B2 (en) 1979-08-31 1984-03-08 Ici Australia Limited Benzotriazines
EP0059524A1 (en) 1981-02-09 1982-09-08 Smith and Nephew Associated Companies p.l.c. Pharmaceutical composition containing aminopteridines or aminopyrimido(4,5-d)pyrimidines
DE3205638A1 (de) 1982-02-17 1983-08-25 Hoechst Ag, 6230 Frankfurt Trisubstituierte pyrimidin-5-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US4490289A (en) 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US5616584A (en) 1986-09-25 1997-04-01 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
JP2598100B2 (ja) 1988-08-31 1997-04-09 キヤノン株式会社 電子写真感光体
US5214059A (en) 1989-07-03 1993-05-25 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
JPH03127790A (ja) 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
US5062685A (en) 1989-10-11 1991-11-05 Corning Incorporated Coated optical fibers and cables and method
GB9003553D0 (en) 1990-02-16 1990-04-11 Ici Plc Herbicidal compositions
JP2839106B2 (ja) 1990-02-19 1998-12-16 キヤノン株式会社 電子写真感光体
MY107955A (en) 1990-07-27 1996-07-15 Ici Plc Fungicides.
GB9016800D0 (en) 1990-07-31 1990-09-12 Shell Int Research Tetrahydropyrimidine derivatives
DE4025891A1 (de) 1990-08-16 1992-02-20 Bayer Ag Pyrimidyl-substituierte acrylsaeureester
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
HUT63941A (en) 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
US5482951A (en) 1992-05-29 1996-01-09 Kumiai Chemical Industry Co., Ltd. Triazole derivatives as well as insecticide and acaricide
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH0741461A (ja) 1993-05-27 1995-02-10 Eisai Co Ltd スルホン酸エステル誘導体
JPH0782183A (ja) 1993-09-09 1995-03-28 Canon Inc 液晶中間体化合物、液晶性化合物、高分子液晶化合物、高分子液晶共重合体化合物、それらの組成物、液晶素子および記録装置
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5530000A (en) 1993-12-22 1996-06-25 Ortho Pharmaceutical Corporation Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
DE69636837T2 (de) 1995-09-25 2007-10-25 Sanofi-Aventis U.S. Llc 1,2,4-benzotriazinoxid-formulierungen
US5827850A (en) 1995-09-25 1998-10-27 Sanofi Pharmaceuticals, Inc. 1,2,4-benzotriazine oxides formulations
JPH09274290A (ja) 1996-02-07 1997-10-21 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料用の現像液および処理方法
DK0939632T3 (da) 1996-02-23 2006-01-30 Lilly Co Eli Non-peptidyl vasopressin V1a antagonister
DE59707681D1 (de) 1996-10-28 2002-08-14 Rolic Ag Zug Vernetzbare, photoaktive Silanderivate
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
JP3734903B2 (ja) 1996-11-21 2006-01-11 富士写真フイルム株式会社 現像処理方法
JPH10153838A (ja) 1996-11-22 1998-06-09 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JP3720931B2 (ja) 1996-11-26 2005-11-30 富士写真フイルム株式会社 ハロゲン化銀写真感光材料の処理方法
US5935383A (en) 1996-12-04 1999-08-10 Kimberly-Clark Worldwide, Inc. Method for improved wet strength paper
JPH10207019A (ja) 1997-01-22 1998-08-07 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JPH10213820A (ja) 1997-01-31 1998-08-11 Canon Inc 液晶素子及び液晶装置
DE59807348D1 (de) 1997-02-05 2003-04-10 Rolic Ag Zug Photovernetzbare Silanderivate
JPH10260512A (ja) 1997-03-19 1998-09-29 Fuji Photo Film Co Ltd ハロゲン化銀感光材料の処理方法
US6070126A (en) 1997-06-13 2000-05-30 William J. Kokolus Immunobiologically-active linear peptides and method of identification
WO1998058901A1 (fr) 1997-06-24 1998-12-30 Nikken Chemicals Co., Ltd. Derives de la 3-anilino-2-cycloalcenone
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6685938B1 (en) 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US6136971A (en) 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
AU764479B2 (en) 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6498165B1 (en) * 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
JP4609691B2 (ja) 1999-07-01 2011-01-12 味の素株式会社 複素環化合物及びその医薬用途
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PL353476A1 (en) 1999-07-23 2003-11-17 Shionogi & Co, Ltd. Th2 differentiation inhibitors
US6127382A (en) 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6093838A (en) 1999-08-16 2000-07-25 Allergan Sales, Inc. Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE60025243T2 (de) 1999-10-12 2006-06-22 Takeda Pharmaceutical Co. Ltd. Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
US6153752A (en) 2000-01-28 2000-11-28 Creanova, Inc. Process for preparing heterocycles
US20020165244A1 (en) 2000-01-31 2002-11-07 Yuhong Zhou Mucin synthesis inhibitors
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2001064646A2 (en) 2000-03-01 2001-09-07 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
JP2001247411A (ja) 2000-03-09 2001-09-11 Tomono Agrica Co Ltd 有害生物防除剤
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
MXPA02009763A (es) 2000-04-04 2003-03-27 Shionogi & Co Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa.
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
DE10024622A1 (de) 2000-05-18 2001-11-22 Piesteritz Stickstoff N-(2-Pyrimidinyl)(thio)phosphorsäuretriamide, Verfahren zu ihrer Herstellung und deren Verwendung als Mittel zur Regulierung bzw. Hemmung der enzymatischen Harnstoff-Hydrolyse
US6875483B2 (en) 2000-07-06 2005-04-05 Fuji Photo Film Co., Ltd. Liquid crystal composition comprising liquid crystal molecules and alignment promoter
JP5000068B2 (ja) 2000-08-11 2012-08-15 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有用な複素環化合物
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
JP2002221770A (ja) 2001-01-24 2002-08-09 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
EP1401833A2 (fr) 2001-05-28 2004-03-31 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
EP1392662B1 (de) 2001-05-29 2009-01-07 Bayer Schering Pharma Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
WO2003004492A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
CA2463989C (en) * 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US20060292206A1 (en) * 2001-11-26 2006-12-28 Kim Steven W Devices and methods for treatment of vascular aneurysms
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030166932A1 (en) 2002-01-04 2003-09-04 Beard Richard L. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
WO2003074515A1 (en) 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
JP4570955B2 (ja) 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
IL166528A0 (en) 2002-08-02 2006-01-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
RU2005106871A (ru) 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
DE10240261A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen
DE10240262A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Aryllithium-Basen
EP1549614A4 (en) * 2002-10-03 2008-04-16 Targegen Inc VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
US20050282814A1 (en) 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2004032709A2 (en) 2002-10-04 2004-04-22 Caritas St.Elisabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization
EP1551813A4 (en) 2002-10-10 2007-07-11 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20040132732A1 (en) 2002-10-21 2004-07-08 Wei Han Quinazolinones and derivatives thereof as factor Xa inhibitors
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
BR0315705A (pt) 2002-11-19 2005-09-06 Memory Pharm Corp Inibidores de fosfodiesterase-4
CA2508601A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
WO2004054186A1 (ja) 2002-12-12 2004-06-24 Fujitsu Limited データ中継装置、連想メモリデバイス、および連想メモリデバイス利用情報検索方法
MXPA05006732A (es) 2002-12-20 2005-09-08 Pharmacia Corp El isomero r de compuesto de beta-aminoacido como derivados de antagonistas de receptor de la integrina.
JP2006518333A (ja) 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004058782A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Therapeutic quinazoline derivatives
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
EA010379B1 (ru) 2003-02-07 2008-08-29 Янссен Фармацевтика Н.В. Ингибирующие вич 1,2,4-триазины
CA2515544A1 (en) 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
EP1623269B2 (en) 2003-04-24 2022-08-31 CooperVision International Limited Hydrogel contact lenses and package systems and production methods for same
CA2533320A1 (en) 2003-08-15 2006-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
JP2007505858A (ja) 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
DK2210607T3 (da) 2003-09-26 2011-12-12 Exelixis Inc N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft
WO2005035541A1 (en) 2003-10-07 2005-04-21 Amedis Pharmaceuticals Ltd. Silicon compounds and their use
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
JP4932495B2 (ja) 2004-01-23 2012-05-16 アムゲン インコーポレイテッド 化合物及び使用方法
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
JP5275628B2 (ja) 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
US7210697B2 (en) 2004-12-16 2007-05-01 Tricam International, Inc. Convertible handle
WO2006081172A2 (en) 2005-01-26 2006-08-03 Irm Llc Compounds and compositions as protein kinase inhibitors
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
WO2006101977A2 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
MX2007008848A (es) 2005-06-08 2008-04-16 Targegen Inc Metodos y composiciones para el tratamiento de desordenes oculares.
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
EP1940843A4 (en) 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
TW200745066A (en) 2005-09-16 2007-12-16 Torrent Pharmaceuticals Ltd Novel PTP1B inhibitors
US20070072682A1 (en) 2005-09-29 2007-03-29 Crawford James T Iii Head to head electronic poker game assembly and method of operation
CA2628283C (en) * 2005-11-01 2017-06-27 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20070149508A1 (en) 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US7691858B2 (en) 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
WO2009026346A1 (en) 2007-08-20 2009-02-26 Targegen Inc. Thiazolidine compounds, and methods of making and using same
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009055674A1 (en) 2007-10-26 2009-04-30 Targegen Inc. Pyrrolopyrimidine alkynyl compounds and methods of making and using same
EP2254581A1 (en) 2008-02-08 2010-12-01 TargeGen, Inc. Pteridine derivatives for treating respiratory disease
CA2732791A1 (en) 2008-08-05 2010-02-11 Targegen, Inc. Methods of treating thalassemia

Also Published As

Publication number Publication date
IL178908A (en) 2015-09-24
AU2005231507A1 (en) 2005-10-20
WO2005096784A3 (en) 2009-02-19
RU2006139258A (ru) 2008-05-20
WO2005096784A2 (en) 2005-10-20
NZ588139A (en) 2012-02-24
US7456176B2 (en) 2008-11-25
US20090275569A1 (en) 2009-11-05
US20110294796A1 (en) 2011-12-01
EP1809614A2 (en) 2007-07-25
US8481536B2 (en) 2013-07-09
EP1809614A4 (en) 2010-02-17
IL178908A0 (en) 2011-08-01
US20050245524A1 (en) 2005-11-03
CA2567574A1 (en) 2005-10-20
EP2543376A1 (en) 2013-01-09
EP1809614B1 (en) 2014-05-07
NZ551027A (en) 2011-01-28
AU2005231507B2 (en) 2012-03-01
CA2567574C (en) 2013-01-08
HK1110578A1 (en) 2008-07-18

Similar Documents

Publication Publication Date Title
KR20070011458A (ko) 키나제의 벤조트리아진 억제제
RU2589878C2 (ru) Би-арил-мета-пиримидиновые ингибиторы киназ
ES2759480T3 (es) Nuevos derivados de hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
EP2991982B1 (en) Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
MX2007011500A (es) Compuestos pirimidina y metodos de uso.
KR20180122406A (ko) 피리미딘 및 그의 변이체, 및 그의 용도
WO2007056075A2 (en) Six membered heteroaromatic inhibitors targeting resistant kinase mutations
CN111269215B (zh) 含氮杂环有机化合物及其制备方法和应用
CN101426772B (zh) 激酶的苯并三嗪抑制物
AU2012202928A1 (en) Benzotriazine inhibitors of kinases
MX2008005810A (en) Bi-aryl meta-pyrimidine inhibitors of kinases

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid